Study about autoantibodies targeting GPCR in PACVS

A new study about autoantibodies targeting G-Protein-Coupled Receptors (GPCRs) in Post-Acute COVID Vaccination Syndrome (PACVS) was published. This study included 17 patients with symptoms compatible with PACVS after COVID-19 vaccination but they had not been infected with SARS-CoV-2. Serological tests showed that a high percentage of patients were positive for autoantibodies against GPCRs which are…

Details

Christmas Holidays 2024

  The entire CellTrend team wishes all cooperation partners, customers, friends and patients a Merry Christmas and a healthy New Year 2025! Please note that our laboratory will be closed from 23.12.24 to 01.01.25 and no samples will be taken during this time. We will be back for you as usual from Thursday, 02.01.25.  

Details

Camera team visited CellTrend

A camera team from RBB visited the biotechnology park. In order to be able to expand, new areas are needed in the biotechnology park. The possibilities are there, but the financing is still lacking. In the report you can see a statement by Prof. Dr. Kai Schulze Forster. Watch the RBB video.

Impressions of the symposium in Lübeck

Prof. Dr. Gabriela Riemekasten hosted the 5th International Symposium on Regulatory Autoantibodies in Lübeck. Many guests, including international guests, accepted the invitation to the Hanseatic city. Once again this year, numerous interesting presentations were given on the topic of GPCRs and their causal relationship in patients was discussed. The methods for eliminating pathogenic autoantibodies and…

Details

5th International Symposium on Regulatory Autoantibodies on September 26-27th, 2024

Save the date! On September 26-27th, 2024, the 5th International Symposium on Regulatory Autoantibodies will take place in Lübeck! Under the direction of Prof. Dr. med. Gabriela Riemekasten, excellent speakers such as Prof. Dr. Carmen Scheibenbogen, Prof. Yehuda Shoenfeld and others will focus on the connection of RABs to the pathogenesis of diseases and their…

Details